Protected: The VESL Wall Issue #12 is now out! This month we feature a post-hoc analysis of the heart failure subset in the REDUCE-IT trial with icosapent ethyl, the Phase 2 dose-finding study of the antisense agent vupanorsen, and a new review on the role of Lp(a) in familial hypercholesterolemia.

This content is password protected. To view it please enter your password below: